Stock Markets January 27, 2026

Uniphar Posts Best Organic Gross Profit Growth Since IPO, EPS Beats Expectations

Full-year 2025 results show 9% organic gross profit expansion and roughly 21% adjusted EPS growth, while net leverage falls below analyst forecasts

By Ajmal Hussain
Uniphar Posts Best Organic Gross Profit Growth Since IPO, EPS Beats Expectations

Uniphar PLC reported robust full-year 2025 results, delivering 9% organic gross profit growth - its strongest rate since listing - and adjusted EPS growth of about 21%, outstripping consensus. Improved financing costs, a completed €35 million buyback, and favorable working capital movements helped reduce net bank debt to EBITDA to 1.5x, well under analyst expectations.

Key Points

  • Uniphar recorded 9% organic gross profit growth for full-year 2025 - the fastest since its IPO.
  • Adjusted EPS rose by approximately 21%, outperforming consensus forecasts of 14% largely due to lower finance costs and a completed €35 million buyback.
  • Net bank debt to EBITDA was 1.5x at year-end, roughly €90 million lower than forecasts because of favourable working capital timing; company keeps €200 million EBITDA by 2028 target including €20 million from M&A.

Overview

Uniphar PLC (ISE:UPR) on Tuesday released full-year 2025 results that showed material improvements across profitability and leverage metrics. Organic gross profit rose 9% - the fastest pace since the company went public. Adjusted earnings per share expanded by roughly 21%, a performance that exceeded both the company's internal outlook and the market consensus of 14%.


Drivers of outperformance

Management attributed the stronger-than-expected adjusted EPS primarily to lower finance costs and the effects of a completed share buyback. During the reporting period the company finished a €35 million buyback program, which contributed to EPS upside alongside reduced interest expense.

Working capital movements also played a notable role. Net bank debt to EBITDA ended the year at 1.5x - materially below analysts' projections of 2.2x - supported by timing benefits in working capital. The company's net debt position was roughly €90 million lower than forecasts, a difference the company linked to those same working capital dynamics.


Guidance and divisional outlook

Uniphar reiterated its target of achieving €200 million EBITDA by 2028. That goal incorporates an anticipated €20 million contribution from mergers and acquisitions. Looking nearer term, the company confirmed divisional organic gross profit growth expectations for 2026: Uniphar Pharma is targeting double-digit growth, Uniphar Medtech is aiming for high single-digit growth, and Uniphar Supply Chain & Retail is expected to deliver low single-digit growth.


Operational programs

Management also reiterated that progress on key operational investments is proceeding as planned. At a recent conference in January, they confirmed that work on a new logistics centre and an upgraded ERP system remains on track for a summer launch.


Takeaway

The results show a combination of organic performance and capital management that together improved profitability and lowered leverage versus market expectations. The company maintains multi-year EBITDA goals while setting clear divisional growth targets for 2026. Working capital timing and completed buybacks were important contributors to the year-end financial position.

Risks

  • Working capital timing materially affected net debt versus forecasts - future timing differences could reverse some of the year-end benefit, impacting leverage - this affects credit and banking sectors as well as investor perception.
  • Guidance depends in part on acquisitions delivering €20 million of EBITDA by 2028 - integration or execution risk in M&A could affect the company’s ability to meet the target - this impacts M&A activity and strategic investors in healthcare services.
  • Operational rollouts such as the new logistics centre and ERP system are expected for summer launch; any delay or implementation issues could influence divisional performance and cost profiles - this impacts supply chain and enterprise software deployment within the healthcare sector.

More from Stock Markets

Indian equities rally after U.S. agrees tariff reductions in trade accord Feb 2, 2026 SiTime Nears Acquisition of Renesas Timing Business in Potential $3 Billion Deal Feb 2, 2026 Tesla Debuts New All-Wheel Drive Model Y Trim in U.S.; Premium Option Also Launched Feb 2, 2026 Eastroc Beverage Shares Start Trading in Hong Kong at Offer Price After $1.3 Billion IPO Feb 2, 2026 SoftBank unit and Intel to jointly develop 'Z-Angle' memory technology Feb 2, 2026